Diabetic Foot Ulcer Biofilm Infection and Recurrence
糖尿病足溃疡生物膜感染和复发
基本信息
- 批准号:10947670
- 负责人:
- 金额:$ 60.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-07 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Abstract
Diabetic foot ulcers (DFU) are one of the most common reason for hospitalization of diabetic patients and
frequently it results in amputation of lower limbs. Of the one million people who undergo non-traumatic leg
amputations annually worldwide, 75% are performed on people who have type 2 diabetes (T2DM). The risk of
death at 10 years for a diabetic with DFU is twice as high as the risk for a patient without a DFU. The rate of
amputation in patients with DFU is 38.4%. Infection is a common (>50%) complication of DFU. In those with
DFU, 40% recur within one year after wound closure; 60% within 3 years, and 65% within 5 years. Thus, the
strongest predictor of DFU is a previous foot ulcer. The proposed work rests on a series of pre-clinical and
clinical findings laying the foundation to the hypothesis that biofilm infection of DFU compromises barrier
function of the closed DFU. Such deficient closure paves the way to DFU recurrence. Biofilms are estimated to
account for 60% of chronic wound infections. In the biofilm form, bacteria are in a dormant metabolic state. The
standard clinical techniques like colony forming units (CFU) assay to detect infection may not detect biofilm
infection. Thus, biofilm infection may be viewed as a silent maleficent threat in wound care. The proposed work
is a two-center study – Indiana University and Stanford University – who were competitively funded with a pilot
award by the NIDDK-DIACOMP mechanism to generate preliminary data on DFU closure and recurrence. The
proposed work addresses a novel paradigm in DFU care that has never been tested in a fully powered patient-
based study. Successful execution of the proposed work is likely to have direct impact on the current standards
of wound care including re-defining the most important primary endpoint of wound care, wound closure itself.
For the first time in a DFU patient-based study, mechanisms by which biofilm infection induces molecular
mechanisms that compromise functional integrity of re-epithelialized DFU will be elucidated. In DFU care, the
proposed work may identify that the current endpoint of wound closure (that does not account for any
functional parameter) may be not the right time to stop caring for DFU. That such premature termination of
care may be responsible for the high recurrence of DFU that is currently reported. The notion that continued
care, until functional wound closure is achieved, is necessary to minimize recurrence and amputation would be
of transformative value in the delivery of DFU care. This proposal, wholly based on the study of DFU patients
seeks to conduct a two-centered robust clinical study testing whether wounds with a history of biofilm infection
closes with deficient barrier function (Aim 2). Aim 3 tests whether such deficient wound closure which
manifests as high TEWL is associated with greater wound recurrence. Aim 1 utilizes this patient-based study to
address molecular mechanisms implicated in biofilm-induced loss of skin epithelial barrier integrity.
摘要
糖尿病足溃疡(DFU)是糖尿病患者住院的最常见原因之一,
经常导致下肢截肢。在一百万接受非创伤性腿部手术的人中,
在全世界每年进行的截肢手术中,75%是在患有2型糖尿病(T2 DM)的人身上进行的。的风险
糖尿病合并糖尿病足溃疡患者10年死亡的风险是未合并糖尿病足溃疡患者的两倍。率
DFU患者截肢率为38.4%。感染是DFU的常见并发症(>50%)。在那些与
DFU,40%在伤口闭合后1年内复发; 60%在3年内复发,65%在5年内复发。因此
DFU的最强预测因子是既往足部溃疡。拟议的工作依赖于一系列临床前和
为DFU生物膜感染损害屏障的假设奠定基础的临床发现
关闭DFU的功能。这种闭合缺陷为DFU复发铺平了道路。生物膜估计
占慢性伤口感染的60%。在生物膜形式中,细菌处于休眠代谢状态。的
用于检测感染的标准临床技术如集落形成单位(CFU)测定可能检测不到生物膜
感染因此,生物膜感染可能被视为伤口护理中无声的恶意威胁。拟议工作
是一项两个中心的研究--印第安纳州大学和斯坦福大学--他们得到了一个试点项目的竞争性资助
由NIDDK-DIACOMP机制授予,以生成关于DFU关闭和复发的初步数据。的
拟议的工作解决了DFU护理中的一种新范式,这种范式从未在完全动力的患者中进行过测试-
基于研究。建议工作的成功执行可能会对现行标准产生直接影响
包括重新定义伤口护理的最重要的主要终点,伤口闭合本身。
在DFU基于患者的研究中,首次发现了生物膜感染诱导分子生物学改变的机制。
将阐明损害再上皮化DFU功能完整性的机制。在DFU护理中,
所提出的工作可以确定伤口闭合的当前终点(其不考虑任何
功能参数)可能不是停止照顾DFU的正确时机。这种过早的终止
护理可能是目前报道的DFU高复发率的原因。这个概念延续了
护理,直到功能性伤口闭合,是必要的,以尽量减少复发和截肢将是必要的。
在提供DFU护理方面具有变革性价值。该建议完全基于对DFU患者的研究
旨在进行一项双中心的稳健临床研究,测试具有生物膜感染史的伤口是否
关闭缺陷屏障功能(目标2)。目的3测试这种缺陷的伤口闭合,
表现为高TEWL与更大的伤口复发相关。目的1利用这项基于患者的研究,
解决生物膜诱导的皮肤上皮屏障完整性丧失中涉及的分子机制。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Electrochemical Devices in Cutaneous Wound Healing.
- DOI:10.3390/bioengineering10060711
- 发表时间:2023-06-11
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GEOFFREY C GURTNER其他文献
GEOFFREY C GURTNER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GEOFFREY C GURTNER', 18)}}的其他基金
TARGETING HIF-1α DYSFUNCTION TO TREAT PRESSURE ULCERS IN THE AGED
针对 HIF-1α 功能障碍治疗老年人压疮
- 批准号:
10685482 - 财政年份:2022
- 资助金额:
$ 60.71万 - 项目类别:
TARGETING HIF-1α DYSFUNCTION TO TREAT PRESSURE ULCERS IN THE AGED
针对 HIF-1α 功能障碍治疗老年人压疮
- 批准号:
10444745 - 财政年份:2022
- 资助金额:
$ 60.71万 - 项目类别:
Diabetic Foot Ulcer Biofilm Infection and Recurrence
糖尿病足溃疡生物膜感染和复发
- 批准号:
10417228 - 财政年份:2020
- 资助金额:
$ 60.71万 - 项目类别:
Diabetic Foot Ulcer Biofilm Infection and Recurrence
糖尿病足溃疡生物膜感染和复发
- 批准号:
10256045 - 财政年份:2020
- 资助金额:
$ 60.71万 - 项目类别:
Diabetic Foot Ulcer Biofilm Infection and Recurrence
糖尿病足溃疡生物膜感染和复发
- 批准号:
10044343 - 财政年份:2020
- 资助金额:
$ 60.71万 - 项目类别:
Diabetic Foot Ulcer Biofilm Infection and Recurrence
糖尿病足溃疡生物膜感染和复发
- 批准号:
10376509 - 财政年份:2020
- 资助金额:
$ 60.71万 - 项目类别:
Stanford Advanced Wound Care Center Clinical Research Unit
斯坦福高级伤口护理中心临床研究部
- 批准号:
10203948 - 财政年份:2018
- 资助金额:
$ 60.71万 - 项目类别:
Stanford Advanced Wound Care Center Clinical Research Unit
斯坦福高级伤口护理中心临床研究部
- 批准号:
10377776 - 财政年份:2018
- 资助金额:
$ 60.71万 - 项目类别:
Stanford Advanced Wound Care Center Clinical Research Unit
斯坦福高级伤口护理中心临床研究部
- 批准号:
10230438 - 财政年份:2018
- 资助金额:
$ 60.71万 - 项目类别:
The University of Arizona Wound Care Center Clinical Research Unit
亚利桑那大学伤口护理中心临床研究单位
- 批准号:
10877642 - 财政年份:2018
- 资助金额:
$ 60.71万 - 项目类别:
相似海外基金
Establishment of diabetic foot ulcer management using the diabetic foot ulcer healing process monitoring scale
利用糖尿病足溃疡愈合过程监测量表建立糖尿病足溃疡管理
- 批准号:
23H03193 - 财政年份:2023
- 资助金额:
$ 60.71万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Randomized controlled trial of continuous glucose monitoring compared to point of care glucose testing following hospital discharge on 12-week diabetic foot ulcer healing rates
连续血糖监测与出院后护理点血糖测试对 12 周糖尿病足溃疡愈合率的随机对照试验
- 批准号:
10727731 - 财政年份:2023
- 资助金额:
$ 60.71万 - 项目类别:
Semi-Autonomous Electrical Stimulation Therapy Device to Promote Faster Recovery for Patients with Diabetic Foot Ulcer
半自主电刺激治疗装置可促进糖尿病足溃疡患者更快康复
- 批准号:
559173-2021 - 财政年份:2022
- 资助金额:
$ 60.71万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
A rapid point-of-care test for early prediction diabetic foot ulcer pathogenesis
早期预测糖尿病足溃疡发病机制的快速护理点测试
- 批准号:
10047069 - 财政年份:2022
- 资助金额:
$ 60.71万 - 项目类别:
Grant for R&D
Improving Diabetic Foot Ulcer Offloading: A Pilot Study on the Impact of Removable Cast Walker Design Factors on Usability
改善糖尿病足溃疡减轻负担:可拆卸石膏助行器设计因素对可用性影响的初步研究
- 批准号:
10654030 - 财政年份:2022
- 资助金额:
$ 60.71万 - 项目类别:
Improving Diabetic Foot Ulcer Offloading: A Pilot Study on the Impact of Removable Cast Walker Design Factors on Usability
改善糖尿病足溃疡减轻负担:可拆卸石膏助行器设计因素对可用性影响的初步研究
- 批准号:
10521884 - 财政年份:2022
- 资助金额:
$ 60.71万 - 项目类别:
Inflammation-related gene biomarkers in human diabetic foot ulcer healing
人类糖尿病足溃疡愈合中的炎症相关基因生物标志物
- 批准号:
10658986 - 财政年份:2022
- 资助金额:
$ 60.71万 - 项目类别:














{{item.name}}会员




